On behalf of our 650+ member organizations, MassBio would like to thank the members of the Senate Judiciary Committee for incorporating needed reforms to the PTO’s inter partes review (IPR) and post-grant review (PGR) proceedings into the PATENT Act. These reforms will go a long way in addressing our concerns about the basic fairness of IPR and PGR proceedings to patent owners.
We remain committed to working with BIO and our member companies to press for further IPR improvements necessary to ensure that the PATENT Act reflects an appropriate balance between the interests of those who seek to enforce patent rights and those who are accused of infringement.
Biotechnology companies rely upon the strength of their patents to raise and invest the hundreds of millions of dollars needed to discover, develop and bring to market their innovative products. A fair and balanced patent law helps ensure new treatments and cures continue to be developed for the patients around the world who need them.